Cargando…

A Response to: Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis

Detalles Bibliográficos
Autores principales:	Armstrong, April W., Soliman, Ahmed M., Betts, Keith A., Wang, Yan, Gao, Yawen, Stakias, Vassilis, Puig, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674807/ https://www.ncbi.nlm.nih.gov/pubmed/36271222 http://dx.doi.org/10.1007/s13555-022-00812-z

Ejemplares similares

Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
por: Armstrong, April W., et al.
Publicado: (2021)

Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
por: Armstrong, April W., et al.
Publicado: (2021)

Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
por: Pettitt, Dan, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
por: Armstrong, April W., et al.
Publicado: (2023)

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
por: Armstrong, April W., et al.
Publicado: (2023)

Authors’ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Pope, Janet, et al.
Publicado: (2021)

Letter to Editor Regarding the OCEAN Study [Letter]
por: Yawn, Barbara P, et al.
Publicado: (2021)

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
por: Armstrong, April, et al.
Publicado: (2022)

Reply to Letter to the Editor Regarding Article: “Considering the Potential Benefits of Over-The-Counter Naloxone” [Response To Letter]
por: Evoy, Kirk E, et al.
Publicado: (2021)

Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2015)

Letter to the Editor Regarding Vaping Article
por: Spitz, Rabbi Yehuda
Publicado: (2019)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials
por: Strober, B.E., et al.
Publicado: (2018)

Response letter regarding the letter to the editors by Brown et al.
por: Taylor, Sylvia, et al.
Publicado: (2016)

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
por: Lambert, Jo, et al.
Publicado: (2021)

Letter to the editor: Regarding the editorial by Penttinen and Friede
por: Fry, Alicia M, et al.
Publicado: (2016)

Letter to the Editor Regarding “Letter to the Editor: Spinal and Neurosurgical Publications During the COVID-19 Era”
por: Akhaddar, Ali, et al.
Publicado: (2020)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
por: Egeberg, Alexander, et al.
Publicado: (2023)

Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model
por: Papp, Kim A., et al.
Publicado: (2021)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up
por: Papp, K.A., et al.
Publicado: (2021)

Letter to the Editor Regarding: A Comprehensive Review on Copemyl(®)
por: Comi, Giancarlo, et al.
Publicado: (2018)

Letter to the editor regarding “Rotavirus infection beyond the gut”
por: Orrico-Sánchez, Alejandro, et al.
Publicado: (2019)

Letter to the Editor: Regarding “The Role of Obesity in Pediatric Orthopedics”
por: Rehm, Andreas, et al.
Publicado: (2020)

Letter to the editor regarding the paper “Tick infestation of the eyelid”
por: Dantas-Torres, Filipe
Publicado: (2020)

Letter to the Editor: Regarding COVID-19 in Children with Asthma
por: Özdemir, Öner
Publicado: (2021)

Letter to the editor regarding the article of Chen et al.
por: Islamoglu, Mehmet Sami, et al.
Publicado: (2022)

Letter to the Editor Regarding “Ultrasound Features of Adhesive Capsulitis”
por: Boudier-Revéret, Mathieu, et al.
Publicado: (2022)

Letter to the editor regarding “Selfies: A boon or bane?”
por: Kazerooni, Rashid
Publicado: (2022)

Letter to the Editor Regarding: Evolving Business Models in Orthotics
por: Laakso, L.
Publicado: (2022)

Letter to the editor regarding “unusual extraneural metastasis of glioblastoma”
por: Waack, Andrew Leland, et al.
Publicado: (2023)

Letter to Editor regarding “Unusual Presentation of Spontaneous Chylothorax”
por: Varghese, Anjali Rachel, et al.
Publicado: (2022)

Letters to the Editor. Benefits to UK of staying in CERN
Publicado: (1984)

Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
por: Moore, Angela Y, et al.
Publicado: (2010)

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
por: Egeberg, Alexander, et al.
Publicado: (2023)

Moderate and severe plaque psoriasis: cost-of-illness study in Italy
por: Colombo, GL, et al.
Publicado: (2008)

The experience of pain and redness in patients with moderate to severe plaque psoriasis
por: Martin, Mona L., et al.
Publicado: (2015)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vb18ti0lpfaistto71oc82su3c